

Jedan *dokazan* portfolio. To je naš *temelj*.

Najviše iskustva u sveobuhvatnom genomskom profiliranju (CGP)¹



1.000+

Recenziranih publikacija o sadašnjoj i potencijalnoj primjeni sveobuhvatnog genomskog profiliranja¹

1,5 mil.+

Isporučenih nalaza Foundation Medicine¹

→ Sveobuhvatno genomsko profiliranje iz tkiva i krvi, s oznakom CE-IVD, za sve solidne tumore: FoundationOne®CDx i FoundationOne®Liquid CDx.^{3,4}

→ Foundation Medicine testovi sveobuhvatnog genomskog profiliranja izvode se u laboratorijama akreditiranim prema CAP-u i certificiranim prema CLIA-i i ISO-u.¹⁰

RAZUMIJEVANJE NALAZA

- Za pitanja o nalazima pacijenata obratite se našem stručnom timu Medical Affairs.
- Stručna podrška za tumačenje CGP nalaza putem P2P Advice platforme povezuje vas s kolegama za brze i pouzdane odgovore na vaša pitanja.

INTEGRACIJA U RADNI TOK

- Digitalno naručivanje, praćenje i preuzimanje nalaza
- Brz pristup putem pametnog telefona uz MyFMI aplikaciju

IZVRŠNA KORISNIČKA PODRŠKA

- Namjenski tim za tehničku, naučnu i medicinsku podršku korisnicima
- Jednostavno online naručivanje i praćenje slučajeva uz digitalne nalaze u različitim formatima (PDF, JSON podaci, interaktivni nalaz FoundationReport+)
- Dodatne usluge uz testiranje: edukacija, razmjena podataka i kolegijalna podrška u tumačenju nalaza

Jedinstven CGP portfolio s ujednačenim kvalitetom testiranja tkiva i krvi



Razmotrite tečnu biopsiju ako je uzorak tkiva star, iscrpljen, teško dostupan ili premalen, ili kada tumor postane otporan na terapiju. Preporučuje se i kada je brži nalaz klinički važan.²



Razmotrite testiranje tkiva kada je lako dostupno ili kada je tumorska frakcija ctDNA u nalazu tečne biopsije ispod 1%.⁹



Odaberite Foundation Medicine rješenja za jasan, detaljan, sveobuhvatan i validiran CGP nalaz, koji se redovno isporučuje za 8 dana.[†]

Naš dokazani portfolio



SVI SOLIDNI TUMORI

BIOPSIJA TKIVA

TEČNA BIOPSIJA



HEMATOLOŠKI MALIGNITETI

I SARKOMI

FOUNDATIONONE® CDx

- CE-IVD³
- DNA (324 gena)⁵
- TMB, MSI-H, pan-tumorski HRDsig*
- Pouzdana detekcija fuzija iz DNA
- 570+ patološki različiti tipova tumor⁸
- Mogućnost prelaska na tečnu biopsiju

Medijan izrade nalaza: 8,8 dana[†]

FOUNDATIONONE® LIQUID CDx

- CE-IVD⁴
- DNA (324 gena)⁶
- bTMB, MSI-H, tumorska frakcija ctDNA[§]
- Pouzdana detekcija fuzija iz DNA
- Gotovo 100% podudarnost s biopsijom tkiva za pokretačke alteracije kada je ctDNA TF $\geq 1\%$ ⁹
- Mogućnost prelaska na testiranje tkiva

Medijan izrade nalaza: 8 dana[†]

FOUNDATIONONE® HEME

- DNA (406 gena) + RNA (265 gena) za hematološke malignitete, sarkome ili solidne tumore kada je poželjno sekvenciranje RNA⁷
- Tumorsko mutacijsko opterećenje i mikrosatelitska nestabilnost
- FFPE tkivo

Medijan izrade nalaza: 20 dana[†]

IHC

Opcionalno dodatno PD-L1 testiranje tkiva

This service may not be available in all countries. Please consult your local Roche-FMI representative for information regarding the availability of this service (clones) in your country and the specific conditions for its implementation.

TMB: Tumor mutational burden, bTMB: blood tumor mutational burden, MSI: microsatellite instability

Naručite Foundation Medicine test: <https://www.rochefoundationmedicine.com/#/en/international/ordering-support>



* Homologous Recombination Deficiency Signature (HRDsig) is reported as a laboratory professional service that has not been reviewed or approved by the FDA, and is included on our FoundationOne CDx Professional Service page as "HRDsig Positive", "HRDsig Negative" or "Cannot Be Determined".

[†] Data on file, Foundation Medicine, Inc., 2024. Median TAT from sample receipt to report. International markets.

[‡] FoundationOne® Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements in ALK and BRCA1/2 and copy number alterations in BRCA1/2 and ERBB2 (HER2). Comprehensive results across all 324 genes are reported as a laboratory professional service which is not reviewed or approved by the FDA.

[§] bTMB, MSI-H status, and tumor fraction are reported as a laboratory professional service which is not reviewed or approved by the FDA.

References

1. Data on file, Foundation Medicine, Inc, 2025
2. Pascual, J., et al. (2022) Ann Oncol 33(8):750-68. DOI: <https://doi.org/10.1016/j.annonc.2022.05.520>
3. FoundationOne® CDx. Technical specifications, available at <https://www.rochefoundationmedicine.com/#/en/international/foundationone-cdx> (Accessed June 2025)
4. FoundationOne® Liquid CDx. Technical specifications, available at <https://www.rochefoundationmedicine.com/#/en/international/foundationone-liquid-cdx> (Accessed June 2025)
5. Foundation Medicine. FoundationOne® CDx FDA Label. Accessed June, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S014C.pdf
6. Foundation Medicine. FoundationOne® Liquid CDx FDA Label. Accessed June 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190032S010C.pdf
7. FoundationOne® Heme. Technical specifications, available at: <https://www.rochefoundationmedicine.com/#/en/international/foundationone-heme> (Accessed June 2025)
8. Data on file, Foundation Medicine Inc., 2025, and ref
9. Rolfo CD, et al. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024 Jun 3;30(11):2452-2460. doi: 10.1158/1078-0432.CCR-23-3321.
10. Foundation Medicine CAP, CLIA and ISO Certificates available here <https://www.foundationmedicine.com/resource/licenses> (Accessed July 2025)

FoundationOne® Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at <https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine?keycode=454269579>

FoundationOne® CDx and FoundationOne® Liquid CDx are qualitative next-generation sequencing based *in vitro* diagnostic tests for advanced cancer patients with solid tumors and circulating cell-free DNA. For the complete label, including companion diagnostic indications and important risk information, please visit <https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine?keycode=286605475>



© 2025 Foundation Medicine, Inc. | Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc. rochefoundationmedicine.com | MC--17811 | Date of Preparation: July 2025

Roche farmacevtska družba d.o.o.
Stegne 13g
1000 Ljubljana, Slovenia
slovenia.diagnostics@roche.com
<https://diagnostics.roche.com/>

Roche d.o.o.
Ulica grada Vukovara 269a
10000 Zagreb, Croatia
croatia.diagnostics@roche.com
<https://diagnostics.roche.com/>

For HCPs only
MC-HR-02357